MKI67 and neoplasm: Further studies 3, 4, included in the European Neuroendocrine Tumor Society (ENETS) 2017 Guidelines on POD‐GEP neoplasms 6, revealed that a 55% Ki‐67 cut off can discriminate POD‐NENs with different median overall survival (OS) and response to therapy.